Business Context and Reporting Period
Company: ONTO INNOVATION INC.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended September 27, 2025 (Fiscal Year 2025 is a 53-week year).
Business Overview: Onto Innovation designs, develops, manufactures, and supports metrology and inspection tools for the semiconductor industry, serving front-end and back-end manufacturing markets.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $218,193 | $252,210 | $738,397 | $723,382 |
| Gross Profit | $110,623 | $136,379 | $375,978 | $382,900 |
| Gross Margin | 50.7% | 54.1% | 50.9% | 52.9% |
| Operating Income | $23,688 | $53,072 | $119,069 | $144,642 |
| Net Income | $28,224 | $53,051 | $126,230 | $152,853 |
| Diluted EPS | $0.57 | $1.07 | $2.57 | $3.08 |
| Operating Cash Flow (9M) | $233,319 (2025) vs $189,677 (2024) | |||
| Cash & Marketable Securities | $983.9 million (as of Sept 27, 2025) |
Material Changes vs. Prior Period
- Revenue Decline (QoQ): Q3 2025 revenue decreased 14% compared to Q2 2025, driven by lower sales to DRAM and NAND customers in the advanced node market and reduced sales to foundry customers in specialty devices and advanced packaging.
- Revenue Growth (YoY): Nine-month revenue increased 2% year-over-year, offsetting the Q3 decline.
- Margin Compression: Gross margin decreased to 50.7% in Q3 2025 from 54.1% in Q3 2024. This was primarily due to restructuring and other expenses, specifically write-downs of excess and obsolete inventory.
- Operating Expenses: Total operating expenses decreased 3% quarter-over-quarter due to lower restructuring expenses and R&D project costs. However, R&D expenses increased year-over-year due to higher compensation and depreciation.
- Restructuring Costs: Restructuring and other expenses totaled $11.4 million for the nine months ended September 27, 2025, compared to $3.0 million in the prior year period, largely due to business transformation projects and inventory write-downs.
Guidance, Outlook, and Risks
- Acquisition Activity: The Company entered into an agreement to acquire Semilab USA LLC. Following a DOJ "Second Request," the deal was amended on October 9, 2025, to exclude Semilab's Fourier-Transform infrared spectroscopy reflectometry systems business. The revised purchase price is approximately $432.3 million in cash plus 641,771 shares of common stock (total value approx. $495 million). Closing is anticipated in 2025.
- Regulatory Environment: U.S. export regulations continue to limit the ability to provide certain products to customers in China. The Company is assessing the impact of recent U.S. tariffs and potential countermeasures by foreign countries.
- Tax Legislation: The "One Big Beautiful Bill Act" enacted in July 2025 allows for immediate expensing of domestic R&D and certain capital expenditures. The impact on the current quarter was deemed immaterial, but the Company is evaluating future impacts.
- Liquidity: The Company maintains a $100 million line of credit (unused) and expects existing cash and marketable securities to be sufficient for the next 12 months.
Investor Verification Checklist
- Inventory Valuation: Verify the magnitude and justification of the $27.1 million inventory write-down included in Cost of Goods Sold for the nine months ended September 27, 2025.
- Acquisition Timeline: Monitor the status of the Semilab USA acquisition, specifically the regulatory approval process following the DOJ Second Request and the amended deal terms.
- China Exposure: Assess the specific impact of U.S. export controls and tariffs on revenue from China, which accounted for $56.9 million (9M 2025) of total revenue.
- Customer Concentration: Note that three customers accounted for 21%, 18%, and 14% of revenue in the first nine months of 2025, representing significant concentration risk.
- Share Repurchases: Confirm the remaining authorization of $99.9 million under the $200 million share repurchase program approved in February 2024.